Does anti-IgE therapy with omalizumab decrease endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma?
Our results confirmed that anti-IgE therapy with omalizumab in patients with severe persistent allergic asthma results in decreased expression of ET-1 in the airways. This could be very important in limiting airway inflammation and bronchial structural changes caused by such treatment in asthmatic patients.
Exercise may effectively prevent the initiation of nicotine use in adolescents by reducing the reinforcing effects of nicotine.